Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 2 Top panel shows mean (SE) differences in near-final height (cm) (n = 71) in the AI, GH, and AI/GH groups regardless of length of treatment (n.

Published byLeslie Jones Modified over 6 years ago

Similar presentations

Presentation on theme: "Figure 2 Top panel shows mean (SE) differences in near-final height (cm) (n = 71) in the AI, GH, and AI/GH groups regardless of length of treatment (n."— Presentation transcript:

1 Figure 2 Top panel shows mean (SE) differences in near-final height (cm) (n = 71) in the AI, GH, and AI/GH groups regardless of length of treatment (n = 21, 25, and 25, respectively) (P < .001 within groups; *, P = .19 among groups). Bottom panel shows net gain in height (cm) in the same three groups (*, P = .01 among groups; **, P = .002 between AI and AI/GH groups). Average height and net gain in height of young men of similar ages with height SDS −2.0 are shown for comparison on the far right bars (CDC data). From: Randomized Trial of Aromatase Inhibitors, Growth Hormone, or Combination in Pubertal Boys with Idiopathic, Short Stature J Clin Endocrinol Metab. 2016;101(12): doi: /jc J Clin Endocrinol Metab | Copyright © 2016 by the Endocrine Society

2 Figure 1 Changes in mean (SE) height SDS (top panel) and bone age (bottom panel) over 24 months in the groups treated with AIs, GH, and AI/GH. *, P < (top panel); and **, P = .002 (bottom panel) represent the probability of difference in mean changes between groups for all parameters (ANCOVA). n = 76 (baseline), 72 (12 months), and 65 (24 months). From: Randomized Trial of Aromatase Inhibitors, Growth Hormone, or Combination in Pubertal Boys with Idiopathic, Short Stature J Clin Endocrinol Metab. 2016;101(12): doi: /jc J Clin Endocrinol Metab | Copyright © 2016 by the Endocrine Society

3 Figure 3 Changes in FFM (top panel) and percentage fat mass (%FM) (bottom panel) over 24 months in the AI, GH, and AI/GH groups by DXA [mean (SE)]. FFM, P < .001 within each group; *, P = .015 among groups; %FM, P = .50. AI, ; GH, < .0001; AI/GH, **, P = .003 among groups. n = 76 (baseline), 72 (12 months), 63 (24 months). From: Randomized Trial of Aromatase Inhibitors, Growth Hormone, or Combination in Pubertal Boys with Idiopathic, Short Stature J Clin Endocrinol Metab. 2016;101(12): doi: /jc J Clin Endocrinol Metab | Copyright © 2016 by the Endocrine Society

4 Figure 4 Changes in mean (SE) concentrations of T (top panel), estradiol (middle panel), and IGF-1 (bottom panel) in the AI, GH, and AI/GH groups (*, P < among groups for T and IGF-1; **, P < .001 for estradiol). n = 76 (baseline), 72 (12 months), 65 (24 months). From: Randomized Trial of Aromatase Inhibitors, Growth Hormone, or Combination in Pubertal Boys with Idiopathic, Short Stature J Clin Endocrinol Metab. 2016;101(12): doi: /jc J Clin Endocrinol Metab | Copyright © 2016 by the Endocrine Society

Download ppt "Figure 2 Top panel shows mean (SE) differences in near-final height (cm) (n = 71) in the AI, GH, and AI/GH groups regardless of length of treatment (n."

Similar presentations

Aromatase inhibitors in pediatrics short stature and delayed puberty.

Aromatase inhibitors in pediatrics short stature and delayed puberty.
Date of download: 9/18/2016 From: Treatment of Postmenopausal Osteoporosis with Slow-Release Sodium Fluoride: Final Report of a Randomized Controlled Trial.

Date of download: 9/18/2016 From: Treatment of Postmenopausal Osteoporosis with Slow-Release Sodium Fluoride: Final Report of a Randomized Controlled Trial.
ADULT GROWTH HORMONE DEFICIENCY

ADULT GROWTH HORMONE DEFICIENCY
Figure 1. Mass of rapid insulin secretory bursts and ApEn values in young and old subjects. Increased Disorderliness of Basal Insulin Release, Attenuated.

Figure 1. Mass of rapid insulin secretory bursts and ApEn values in young and old subjects. Increased Disorderliness of Basal Insulin Release, Attenuated.
Figure 2. ROC curves for fasting values (A) and OGTT values (B) for detecting insulin resistance in PCOS women. Sensitivity is plotted against 1 − specificity.

Figure 2. ROC curves for fasting values (A) and OGTT values (B) for detecting insulin resistance in PCOS women. Sensitivity is plotted against 1 − specificity.
Girl, 13-4/12 years old, with constitutional delay in growth and puberty. History revealed a normal growth rate but short stature at all ages. Physical.

Girl, 13-4/12 years old, with constitutional delay in growth and puberty. History revealed a normal growth rate but short stature at all ages. Physical.
The Effects of Growth Hormone and Sex Steroid on Lean Body Mass, Fat Mass, Muscle Strength, Cardiovascular Endurance and Adverse Events in Healthy Elderly.

The Effects of Growth Hormone and Sex Steroid on Lean Body Mass, Fat Mass, Muscle Strength, Cardiovascular Endurance and Adverse Events in Healthy Elderly.
Figure 2. Summary of trial events

Figure 2. Summary of trial events
Figure 1. Twenty-four-hour plasma ACTH concentrations in insomniacs (▪) and controls (○). The thick black line indicates the sleep recording period. The.

Figure 1. Twenty-four-hour plasma ACTH concentrations in insomniacs (▪) and controls (○). The thick black line indicates the sleep recording period. The.
0.24→0.37 mg/kg/week (▲) and 0.37 mg/kg/week ().

0.24→0.37 mg/kg/week (▲) and 0.37 mg/kg/week ().
Fig. 1. Baseline and 3-month infusion protocol

Fig. 1. Baseline and 3-month infusion protocol
Precocious or early puberty in patients with

Precocious or early puberty in patients with
Fig. 1. Time line for investigations

Fig. 1. Time line for investigations
Fig. 1. Kaplan-Meir survival curves for Stoke Cushing's patients, with follow-up duration in years on the x-axis. Number of patients in each subgroup is.

Fig. 1. Kaplan-Meir survival curves for Stoke Cushing's patients, with follow-up duration in years on the x-axis. Number of patients in each subgroup is.
Numbers correspond to section of text addressing selected clinical issue. From: Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice.

Numbers correspond to section of text addressing selected clinical issue. From: Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice.
Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis  Peyman Hadji  Critical Reviews in Oncology.

Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis  Peyman Hadji  Critical Reviews in Oncology.
Fig. 1. Mean BMI and BMI Z-score (se) of the children with AA, TA, and TT genotypes in rs9939609 of the FTO gene. The P values are for the additive model.

Fig. 1. Mean BMI and BMI Z-score (se) of the children with AA, TA, and TT genotypes in rs of the FTO gene. The P values are for the additive model.
Fig. 1. Correlation of TSH with TC, LDL-C, HDL-C, and TG.

Fig. 1. Correlation of TSH with TC, LDL-C, HDL-C, and TG.
Fig. 1. Study enrollment and disposition of participants

Fig. 1. Study enrollment and disposition of participants
Figure 1. Illustrative 24-h serum LH concentration (IRMA) profiles and calculated LH secretory rates as determined by deconvolution analysis in one healthy.

Figure 1. Illustrative 24-h serum LH concentration (IRMA) profiles and calculated LH secretory rates as determined by deconvolution analysis in one healthy.

Similar presentations

Ads by Google